Drugs /

cytarabine

Back to Drugs List

Overview

Generic Name(s):
cytarabine
Trade Name(s):
Udicil, Cytarbel, Arabine, Ara-Cell, Aracytine, Aracytin, Tarabine Pfs, Cytosar-U, Erpalfa, Alexan, and Cytosar
NCI Definition [1]:
An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)

Clinical Trials

View Clinical Trials for cytarabine

Cytarabine has been investigated in 244 clinical trials, of which 179 are open and 65 are closed. Of the trials investigating cytarabine, 2 are early phase 1 (1 open), 56 are phase 1 (32 open), 47 are phase 1/phase 2 (35 open), 76 are phase 2 (57 open), 7 are phase 2/phase 3 (7 open), 45 are phase 3 (39 open), 4 are phase 4 (4 open), and 7 are no phase specified (4 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for cytarabine clinical trials.

Acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia are the most common diseases being investigated in cytarabine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cytarabine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cytarabine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cytarabine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ARA-cell, Aracytin, Aracytine, Cytarbel, Cytosar, Erpalfa, Udicil, Cytosar-U, Tarabine PFS, Alexan, Arabine, cytosine-β-d-arabinofuranoside, 1.beta.-d-arabinofuranosylcytosine, arabinosylcytosine, beta-cytosine arabinoside, 1.beta.-d-arabinofuranosylcytosine, 2(1h)-pyrimidinone, 4-amino-1-beta-d-arabinofuranosyl-, arabinoside, cytosine, cytarabine, 1-beta-d-arabinofuranosylcytosine, beta-cytosine arabinoside, cytarabinum, cytosine-beta-d-arabinofuranoside, ara-c, cytosine-.beta.-arabinoside, cytosine-1-beta-d-arabinofuranoside, u-19920, ara-c, chx-3311, 2(1h)-pyrimidinone, 4-amino-1-beta-d-arabinofuranosyl-, 4-amino-1-beta-d-arabinofuranosyl-2(1h)-pyrimidinone, cytosine arabinoside, cytosar u, 2(1h)-pyrimidinone, 4-amino-1.beta.-d-arabinofuranosyl-, 1-beta-d-arabinofuranosylcytosine, cytarabine hydrochloride, 2(1h)-pyrimidinone, 4-amino-1.beta.-d-arabinofuranosyl-, arabinofuranosyl cytidine, cytosine arabinoside, 4-amino-1-beta-d-arabinofuranosyl-2(1h)-pyrimidinone, u-29920a hcl, 1-.beta.-d-arabinofuranosyl-4-amino-2(1h)pyrimidinone, cytosaru, 1-.beta.-d-arabinofuranosyl-4-amino-2(1h)pyrimidinone, ara c, 1-beta-d-arabinofuranosylcytosine, cytosine-beta-arabinoside, cytarabine [chemical/ingredient], cytosine-.beta.-arabinoside, arabinofuranosylcytosine, 1-.beta.-d-arabinofuranosylcytosine, cytosine arabinoside, wr-28453, cytosine arabinosine hydrochloride, 1714, aracytidine, arabinofuranosylcytosine, cytarabinum, cytarabine, cytarabine (product), 1-beta-d-arabinofuranosyl-4-amino-2(1h)pyrimidinone, aracytidine, u 19920, 287459, starasid, beta-cytosine arabinoside, arabinosylcytosine, 147-94-4, cytarabine (substance), citarabina, .beta.-cytosine arabinoside
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C408
SNOMED ID [1]:
C-78080

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.